HealthPeak reported strong Q2 2026 results with a raised full-year FFO guidance, driven by improving life science fundamentals and robust outpatient medical performance. The company completed a $1 billion recapitalization JV with Brookfield, substantially strengthening its balance sheet and funding future growth. Raised FY2026 FFO guidance to $1.73-$1.77 per share, up 2 cents, citing improved same-store NOI outlook.
HealthPeak reported strong Q2 2026 results with a raised full-year FFO guidance, driven by improving life science fundamentals and robust outpatient medical performance. The company completed a $1 billion recapitalization JV with Brookfield, substantially strengthening its balance sheet and funding future growth. Raised FY2026 FFO guidance to $1.73-$1.77 per share, up 2 cents, citing improved same-store NOI outlook.
Demand in outpatient medical remains strong with cash releasing spreads of 5% and a leasing pipeline expected to accelerate internal growth in 2027. Life science is improving with strong leasing volumes, a 480,000 square foot LOI pipeline, and significant occupancy gains…
Demand in outpatient medical remains strong with cash releasing spreads of 5% and a leasing pipeline expected to accelerate internal growth in 2027. Life science is improving with strong leasing volumes, a 480,000 square foot LOI pipeline, and significant occupancy gains…
Completed Brookfield JV for a 5.6M sq ft outpatient portfolio, raising $1B in cash, with call rights to buy back the stake at a 6.5% unlevered IRR.
Lab total occupancy reached 78.5%, up 140 bps YTD, with strong leasing at Torrey Pines (97% leased including LOIs).
Demand in outpatient medical remains strong with cash releasing spreads of 5% and a leasing pipeline expected to accelerate internal growth in 2027. Life science is improving with strong leasing volumes, a 480,000 square foot LOI pipeline, and significant occupancy gains, particularly in Torrey Pines. Senior housing is seeing strong demand with 260 basis points of occupancy growth and a doubling o
Management noted that capital costs to capture occupancy are generally modest, with around 10% for renewals and 20-25% for new leasing, except for redevelopment assets which may require elevated capital. They emphasized their portfolio advantage in avoiding shell build-outs and keeping capital deployment low.
Management expressed confidence in the recovery of life science and the strength of outpatient medical and senior housing, highlighted by successful strategic partnerships and improved balance sheet.
“From a size perspective, we have seen more in that 25 to 75,000 square foot range, both in the executions as well as the LOI and pipeline bucket.”
“When accounting for executed leases and LOIs, our leased percentage in the submarket increases to 97% from approximately 65% at year-end 2025.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $1.73–$1.77 | $1.75 | RAISED |
| UnitsTOTAL_OCCUPANCY | FY2026 | 79%–79.5% | 79.25% | GUIDED |
Deep relationship with Northside Hospital continues to yield high-quality, pre-leased development projects, underpinning HealthPeak's outpatient growth.
“We're funding highly pre-leased outpatient development projects sourced directly through our relationships, such as the project in Atlanta that we announced last evening.”
… prior exposure to the outpatient medical sector. Both joint ventures allow us to maintain control of strategic buildings and tenant relationships while providing an alternative source of equity capital. We're excited to grow both of those partnerships in the future. Our balance sheet is stronger than it's ever been. Leverage is below five times and we have flexibility to pursue a number of capital allocation alternatives. We're funding highly pre-leased outpatient development projects sourced directly through our relationships, such as the project in Atlanta that we announced last evening. We can also do outpatient acquisitions in our joint ventures with Blackstone and Brookfield where the deal structures generate additional returns to HealthPeak as the operating partner. We also see a unique opportunity in LifeScience to create value via acquisition. LifeScience has been a development game for the past decade, but for the next few years it will be an acquisition game and we have the platform and balance sheet to capitalize on the opportunity. We can also do stock buybacks if and when the stock price is well below intrinsic value. Today that's less attractive, but we did buy …
Brookfield's significant capital deployment into outpatient medical through HealthPeak validates the asset class and provides a scalable JV framework for future growth.
“We're pleased to complete this strategic partnership as the proceeds raised exceed our capital recycling target for the year in a single transaction.”
Thank you, Scott. We continue to execute our plan and have made tremendous progress year to date in our leasing and capital allocation objectives. I'll take a moment on our outpatient medical recapitalization with Brookfield. We're pleased to complete this strategic partnership as the proceeds raised exceed our capital recycling target for the year in a single transaction. With the leadership from our investment team, we've demonstrated our ability to execute scale transactions and partner with leading institutional investment managers. From a structured perspective, HealthSeek will retain a 51% ownership interest in a 5.6 million square foot outpatient medical portfolio and raise a billion dollars of cash proceeds. We will utilize our best-in-class platform and expertise to provide asset management, property management, and leasing services, maintaining day-to-day control of the real estate and preserving our client relationships. Economically, the transaction represents a trailing cash cap rate of 5.9%, and after seven years, we'll have a finite number of call rights to repurchase the non-controlling interest at a price sufficient to provide Brookfield a 6.5% unlevered rate of …
Blackstone is gaining exposure to outpatient medical via HealthPeak's platform, which could lead to further capital deployment and bolster HealthPeak's AUM and fee income.
“Neither Blackstone nor Brookfield had any meaningful prior exposure to the outpatient medical sector. Both joint ventures allow us to maintain control of strategic buildings and tenant relationships”
… much of our renewal leasing. Now we're in the process of rolling out our agentic operating platform. This modern version of HealthPeak is an on the ground operator who generates superior results with our people and platform. We're already seeing a payoff from the strategy. In the past two quarters, two of the largest and most respected real estate investors in the world chose HealthPeak as their operating partner. Neither Blackstone nor Brookfield had any meaningful prior exposure to the outpatient medical sector. Both joint ventures allow us to maintain control of strategic buildings and tenant relationships while providing an alternative source of equity capital. We're excited to grow both of those partnerships in the future. Our balance sheet is stronger than it's ever been. Leverage is below five times and we have flexibility to pursue a number of capital allocation alternatives. We're funding highly pre-leased outpatient development projects sourced directly through our relationships, such as the project in Atlanta that we announced last evening. We can also do outpatient acquisitions in our joint ventures with Blackstone and Brookfield where the deal structures generate …
HealthPeak's lab pipeline is concentrated on smaller tenants (25-75k sq ft) and is seeing a shift from development to acquisition, with early signs of distressed asset opportunities. — Indicates a more normalized, granular leasing market, and signals that larger, capital-intensive CRE players with more distressed assets may face increasing competition from incumbents with strong balance sheets.
Hi, good morning and thanks for the time. I appreciate how succinct the prepared remarks were. Just on the lab and the competitive environment for leasing, you obviously have different players out there with different motivations, highly motivated to push up leasing as you guys are. But just curious if anything has changed with regards to the rate environment, free rent, build out costs, et cetera. And maybe as part of that, if you can comment on any changes in the size of tenants out there, small, medium, large, and where the improvements have been.
Hey Juan, this is Scott Bohn. The only thing I'd add on that too is the From a size perspective, we have seen more in that 25 to 75,000 square foot range, both in the executions as well as the LOI and pipeline bucket. So I think that size range is normalizing as we see the funding environment continue to improve.
Torrey Pines submarket leased percentage increased to 97% from ~65% at year-end 2025, indicating severe supply constraint and strong pricing power in core life science clusters.
… results reflect our focus on driving leasing volumes at our properties, which I would like to highlight by sharing our progress in Torrey Pines, the premier lab submarket in San Diego. The activity we've seen in Torrey is a testament to our team on the ground in our high-quality portfolio, as tenants are seeking core assets and core locations with experienced landlords. This is allowing us to capture an outsized share of the deal volume. When accounting for executed leases and LOIs, our leased percentage in the submarket increases to 97% from approximately 65% at year-end 2025. And ending with senior housing. Health Feast ownership interest in Janus Living is now 74%, which represents approximately $6.5 billion of equity value. For the second quarter, Janus Living delivered total revenue growth of 45%, adjusted EBITDA growth of 34%, and ended the period with cash on the balance sheet and no outstanding debt. Now moving to the balance sheet. We had significant activity during the second quarter into the third quarter against a backdrop of elevated borrowing costs. We have taken prudent steps to manage our debt maturities and maintain flexibility in accessing the capital market. …